Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07340073

Coordinated Reset Deep Brain Stimulation for Parkinson's Disease

Deep brain stimulation (DBS) is a surgical implant procedure for the treatment of Parkinson's Disease (PD) utilizing medical devices approved by the FDA. A novel approach to current DBS approaches is called "Coordinated Reset" DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS (T-DBS) that uses continuous high amplitude and high frequency stimulation. This study will evaluate the safety and short-term efficacy of CR-DBS in PD. The results from this study will significantly advance the development of CR-DBS for the treatment of PD. Findings in this study will also provide the rationale for further development of this novel DBS approach for other neurological and psychiatric disorders.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of Idiopathic Parkinson's Disease
  • Minimum age of 21 years old
  • Will be or has been implanted with the Boston Scientific Vercise Genus Rechargeable DBS system

Exclusion criteria

  • History of musculoskeletal disorders that affect movement of the limbs/gait
  • Other significant neurological disorder
  • Significant psychiatric disorder
  • History of dementia or cognitive impairment that precludes them from getting DBS surgery or per study staff judgment, MacCAT-CR assessment does not deduce that the participant has capacity to consent
  • Other significant medical disorder that could impede study participation
  • Pregnant women

Treatment and study plan

DBS

Device

Deep Brain Stimulation

Primary outcomes

  1. Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III

    Time frame: Through participant study completion, an average of two months

    The MDS-UPDRS is a standard rating scale for PD that has been widely used in clinical settings and PD research. It utilizes a 4-subscale structure and 5-point (Normal = 0 to Severe = 4) severity scale. Part III of the Scale assesses the motor signs of PD through 18 items, with a maximum possible score of 72.

Secondary outcomes

  1. Frequency and Severity of Bradykinesia, Dyskinesia, Tremor, Sleep Quality and Fragmentation Scores Measured via KinetiGraph.

    Time frame: Through participant study completion, an average of two months

    The KinetiGraph PKG system consists of a small watch-device worn on the wrist for collecting data over a period of several days and provides a report that shows how motor symptoms and complications of PD such as bradykinesia, tremor and dyskinesias vary throughout the day. The watch will be worn on the patient's most affected side (indicated by each patient's MDS-UPDRS III scores for two body sides).

  2. Amplitude Decrement via Rapid Alternating Movements (RAMs)

    Time frame: Through participant study completion, an average of two months

    This task assesses hypokinesia and the sequence effect (deterioration of movement amplitude over time). Pronation-supination movements will be performed using a forearm manipulandum. Movement will be visually guided and acoustically paced. Four 60-second trials will be completed each side (right and left arms), with each trial including 4 transitions in movement rate (1.0 or 1.75 Hz). Delsys inertial measurement units (IMUs) will also be used during this task to measure EMG and kinematic data.

  3. Forearm Rigidity

    Time frame: Through participant study completion, an average of two months

    Forearm rigidity will be assessed using a custom-built robotic manipulandum which provides reliable and objective measures of resistance to imposed motion. The device passively imposes sinusoidal movements of the forearm about the pronation-supination axis through a ± 40° range of motion at 1.5 Hz while measuring the angular displacement and resistive torque required to move the limb. Trials will be collected separately for the right and left arms, with or without an activation maneuver (tapping the contralateral hand on the leg), a technique that is used clinically to elicit or enhance rigidity. Delsys inertial measurement units (IMUs) will be used to measure the EMG activities of biceps brachii and pronator teres muscles, as secondary measurements during the task.

  4. Cognitive Measurements (TMT-B)

    Time frame: Through participant study completion, an average of two months

    Trail Making Task-B will evaluate visual scanning, sequencing, cognitive flexibility and processing speed will be completed.

  5. Verbal Fluency Measurement (DKEFS)

    Time frame: Through participant study completion, an average of two months

    DKEFS Verbal Fluency Task will evaluate verbal fluency.

  6. Working Memory Assessment via N-Back Task

    Time frame: Through participant study completion, an average of two months

    Quantitative assessment of accuracy and reaction time as a function of working memory load.

  7. Dyskinesia Assessment via Rush Dyskinesia Rating Scale (RDRS)

    Time frame: Through participant study completion, an average of two months

    RDRS will assess the severity of overall dyskinesias during activities of daily living. A severity rating score of 4 indicates violent dyskinesia and 0 indicates an absence of dyskinesia. This scale can also distinguish chorea from dystonia (the two major types of dyskinesias in PD) and identify the single most disabling form of dyskinesia.

  8. Frequency of participants with adverse events as assessed by CTCAE v6.0

    Time frame: Through participant study completion, an average of two months

    Frequency [between and within] participants with treatment-related adverse events as assessed by CTCAE v6.0. This is a qualitative collection of information via participant report or clinical observation, but will be input as quantitative (e.g., a headache can be classified as "1-Mild, 2-Moderate, and 3-Severe).

  9. Step Length ("Steady-State Gait")

    Time frame: Through participant study completion, an average of two months

    In this gait task, spatial and temporal gait metrics will be obtained using wearable inertial measurement units (IMUs) on the feet, wrists, lumbar, and sternum. Patients will walk for ~1 minute, back and forth along a ~12m walkway, followed by ~1 minute of rest (repeated 5x)

  10. Gait Speed ("Steady-State Gait")

    Time frame: Through participant study completion, an average of two months

    In this gait task, spatial and temporal gait metrics will be obtained using wearable inertial measurement units (IMUs) on the feet, wrists, lumbar, and sternum. Patients will walk for ~1 minute, back and forth along a ~12m walkway, followed by ~1 minute of rest (repeated 5x)

  11. Cadence ("Steady-State Gait")

    Time frame: Through participant study completion, an average of two months

    In this gait task, spatial and temporal gait metrics will be obtained using wearable inertial measurement units (IMUs) on the feet, wrists, lumbar, and sternum. Patients will walk for ~1 minute, back and forth along a ~12m walkway, followed by ~1 minute of rest (repeated 5x)

  12. Step Variability ("Steady-State Gait")

    Time frame: Through participant study completion, an average of two months

    In this gait task, spatial and temporal gait metrics will be obtained using wearable inertial measurement units (IMUs) on the feet, wrists, lumbar, and sternum. Patients will walk for ~1 minute, back and forth along a ~12m walkway, followed by ~1 minute of rest (repeated 5x)

  13. Step Asymmetry ("Steady-State Gait")

    Time frame: Through participant study completion, an average of two months

    In this gait task, spatial and temporal gait metrics will be obtained using wearable inertial measurement units (IMUs) on the feet, wrists, lumbar, and sternum. Patients will walk for ~1 minute, back and forth along a ~12m walkway, followed by ~1 minute of rest (repeated 5x)

  14. Swing Time Variability ("Steady-State Gait")

    Time frame: Through participant study completion, an average of two months

    In this gait task, spatial and temporal gait metrics will be obtained using wearable inertial measurement units (IMUs) on the feet, wrists, lumbar, and sternum. Patients will walk for ~1 minute, back and forth along a ~12m walkway, followed by ~1 minute of rest (repeated 5x)

  15. Frequency of Freezing of Gait ("Steady-State Gait")

    Time frame: Through participant study completion, an average of two months

    In this gait task, spatial and temporal gait metrics will be obtained using wearable inertial measurement units (IMUs) on the feet, wrists, lumbar, and sternum. Patients will walk for ~1 minute, back and forth along a ~12m walkway, followed by ~1 minute of rest (repeated 5x)

  16. Duration of Freezing of Gait ("Steady-State Gait")

    Time frame: Through participant study completion, an average of two months

    In this gait task, spatial and temporal gait metrics will be obtained using wearable inertial measurement units (IMUs) on the feet, wrists, lumbar, and sternum. Patients will walk for ~1 minute, back and forth along a ~12m walkway, followed by ~1 minute of rest (repeated 5x)

  17. Difference in Step Length (w/ and w/o 1-Back; "Dual-Task Effect on Gait")

    Time frame: Through participant study completion, an average of two months

    The dual-task effect on gait will be assessed by repeating the gait task; spatial and temporal gait metrics will be obtained using wearable inertial measurement units (IMUs) on the feet, wrists, lumbar, and sternum. Patients will walk for ~1 minute, back and forth along a ~12m walkway, followed by ~1 minute of rest while the patient performs a 1-back cognitive task.

  18. Difference in Gait Speed (w/ and w/o 1-Back; "Dual-Task Effect on Gait")

    Time frame: Through participant study completion, an average of two months

    The dual-task effect on gait will be assessed by repeating the gait task; spatial and temporal gait metrics will be obtained using wearable inertial measurement units (IMUs) on the feet, wrists, lumbar, and sternum. Patients will walk for ~1 minute, back and forth along a ~12m walkway, followed by ~1 minute of rest while the patient performs a 1-back cognitive task.

  19. Difference in Cadence (w/ and w/o 1-Back; "Dual-Task Effect on Gait")

    Time frame: Through participant study completion, an average of two months

    The dual-task effect on gait will be assessed by repeating the gait task; spatial and temporal gait metrics will be obtained using wearable inertial measurement units (IMUs) on the feet, wrists, lumbar, and sternum. Patients will walk for ~1 minute, back and forth along a ~12m walkway, followed by ~1 minute of rest while the patient performs a 1-back cognitive task.

  20. Difference in Step Variability (w/ and w/o 1-Back; "Dual-Task Effect on Gait")

    Time frame: Through participant study completion, an average of two months

    The dual-task effect on gait will be assessed by repeating the gait task; spatial and temporal gait metrics will be obtained using wearable inertial measurement units (IMUs) on the feet, wrists, lumbar, and sternum. Patients will walk for ~1 minute, back and forth along a ~12m walkway, followed by ~1 minute of rest while the patient performs a 1-back cognitive task.

  21. Difference in Step Asymmetry (w/ and w/o 1-Back; "Dual-Task Effect on Gait")

    Time frame: Through participant study completion, an average of two months

    The dual-task effect on gait will be assessed by repeating the gait task; spatial and temporal gait metrics will be obtained using wearable inertial measurement units (IMUs) on the feet, wrists, lumbar, and sternum. Patients will walk for ~1 minute, back and forth along a ~12m walkway, followed by ~1 minute of rest while the patient performs a 1-back cognitive task.

  22. Difference in Swing Time Variability (w/ and w/o 1-Back; "Dual-Task Effect on Gait")

    Time frame: Through participant study completion, an average of two months

    The dual-task effect on gait will be assessed by repeating the gait task; spatial and temporal gait metrics will be obtained using wearable inertial measurement units (IMUs) on the feet, wrists, lumbar, and sternum. Patients will walk for ~1 minute, back and forth along a ~12m walkway, followed by ~1 minute of rest while the patient performs a 1-back cognitive task.

Study contacts

Contact information is provided by the study sponsor or research team.

Kaylee Lymon, PhD

CONTACT

[email protected]

612-626-0877

Sponsors and collaborators

Lead sponsor

University of Minnesota

Other

Registry information

Acronym: CR DBS PD

Important dates

Study start
2026
Primary completion
2031
Study completion
2031
First posted
Jan 14, 2026
Registry last updated
Jul 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.